Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Herein, we report the accumulated efficacy data and safety findings of 54-week netakimab treatment during the PATERA study.The ai...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. A. Sevastyanova, A. V. Eremeeva
Format: Article
Language:Russian
Published: IMA PRESS LLC 2021-03-01
Series:Научно-практическая ревматология
Subjects:
netakimab
psoriatic arthritis
interleukin-17 inhibitors
Online Access:https://rsp.mediar-press.net/rsp/article/view/2989
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items